Arkolith/Insider Trading/CTMX/Form 4

Ogden Christopher

Chief Financial OfficerCytomX Therapeutics, Inc. (CTMX) · full profile →Form 4 · filed Jun 17, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$33K
Net Open-Market Flow
-$33K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 16, 2025Sell(S)11K$2.69$29K226K
Jun 13, 2025Option exercise(M)38K—$0237K
Jun 13, 2025Sell(S)2K$2.95$5K199K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 13, 2025Option exercise(M)38K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-25-000236) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML